(1 - 17 von 17
)
UPDATE 2-Arpida at all-time low on funding concerns | Reuters
www.reuters.com
Shares in Swiss biotech company Arpida slumped to an all-time low of Swiss francs on concerns the company could need fresh funding even after it...
Arpida gibt die Hoffnung noch nicht ganz auf | Handelszeitung
www.handelszeitung.ch
Der Forschungschef, Sergio Lociuro, und der Entwicklungschef, Paul Hadvary, werden das Unternehmen zudem «im gegenseitigen Einvernehmen» verlassen. › Unternehmen
UPDATE 1-Arpida says cost cuts to stem cash burn
www.finanznachrichten.de
Arpida also announced Sergio Lociuro, Head of Research, and Paul Hadvary, Head of Development, would be leaving. The news comes after ...
42,313,150 Ordinary Shares of Motif Bio plc are subject to a Lock-Up ...
www.marketscreener.com
... Michael Floyd, Khalid Islam, Sergio Lociuro and Brad Spellberg and Locked-in CPN Holders will be under lock-up for 12 months following admission. › ...
UPDATE 2-Arpida at all-time low on funding concerns
www.finanznachrichten.de
It also said Sergio Lociuro, Head of Research, and Paul Hadvary, Head of Development, would be leaving. Arpida said it expected to receive a ...
Antibiotic Resistance: EU SME alliance calls for specific support to...
european-biotechnology.com
(from right to left: Olivier Litzka from French investor Edmond de Rothschild (r.), Sergio Lociuro (CSO, Bioversys), Rasmus Toft-Kehler (CSO, ...
BIOVERSYS receives CARB-X Award of up to US$ Mio ...
www.technologiepark.ch
Dr. Sergio Lociuro, CSO of BioVersys: “We are pleased to receive this award from CARB-X and continue the discovery and development of new pyrrolocytosine ... › ...
BioVersys AG raises CHF5 million in Series A2 round
www.startupticker.ch
... in animal models looks so promising that we can't wait to bring this new treatment option to patients in need” said Sergio Lociuro, CSO.
Arpida cuts 75% of workforce "in order to buy time" - PharmaTimes
www.pharmatimes.com
Switzerland’s Arpida says that its board of directors has approved a recently-announced set of cost-cutting measures as it gets to grips with a US regulatory...
Antibiotic used to treat tuberculosis could be superbug treatment
news.usc.edu
— ... in La Jolla; and Vincent Trebosc, Christian Kemmer, Sergio Lociuro and Glenn Dale of BioVersys AG in Basel, Switzerland. › acinetobacte...
BioVersys Receives CARB-X Award of up to B3C newswire
www.b3cnewswire.com
— Dr. Sergio Lociuro, CSO of BioVersys: “CARB-X funding of our BV200 series is a strong validation of BioVersys' approach to drugging new ... › bi...
BioVersys Receives CARB-X Award of up to US$ Million ...
www.pharmasources.com
— Dr. Sergio Lociuro, CSO of BioVersys: "CARB-X funding of our BV200 series is a strong validation of BioVersys' approach to drugging new ... › ...
BioVersys receives US$ million funding from CARB-X to ...
www.pharmabiz.com
— Dr. Sergio Lociuro, CSO of BioVersys: “CARB-X funding of our BV200 series is a strong validation of BioVersys' approach to drugging new ... › News...
BioVersys' second drug candidate enters clinical trials
www.startupticker.ch
— ... faster-acting and active against Eto-Pto- and INH-resistant strains,” said Sergio Lociuro, Chief Scientific Officer of BioVersys. › news
CARB-X is funding Swiss pharma company BioVersys to ...
carb-x.org
— Sergio Lociuro, CSO of BioVersys: “We are pleased to receive this award from CARB-X and continue the discovery and development of new ... › carb-x-news
CARB-X: Bioversys erhält bis zu 12,6 Mio. Euro - Transkript
transkript.de
— Sergio Lociuro, CSO von BioVersys, betont: "Neuartige Klassen von Breitbandantibiotika mit nachgewiesener In-vitro- und In-vivo-Aktivität ... › news › carb-x-bioversys-erhaelt-b...
Second financing for BioVersys from CARB-X - AMR Conference
amr-conference.com
— Dr. Sergio Lociuro, CSO of BioVersys: “We are pleased to receive this award from CARB-X and continue the discovery and development of new ... › news
sortiert nach Relevanz / Datum